- Home
- JAZZ vs EXEL Comparison
JAZZ vs EXEL Comparison
Compare JAZZ & EXEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | JAZZ | EXEL |
|---|---|---|
| Founded | 2003 | 1994 |
| Country | Ireland | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.8B | 11.1B |
| IPO Year | 2007 | 2000 |
Fundamental Metrics
Financial Performance| Metric | JAZZ | EXEL |
|---|---|---|
| Price | $169.80 | $46.01 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 15 | 24 |
| Target Price | ★ $199.20 | $45.18 |
| AVG Volume (30 Days) | 1.1M | ★ 2.8M |
| Earning Date | 11-05-2025 | 02-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 53.55 |
| EPS | N/A | ★ 2.38 |
| Revenue | ★ $4,157,832,999.00 | $2,288,218,000.00 |
| Revenue This Year | $6.00 | $9.84 |
| Revenue Next Year | $6.84 | $11.92 |
| P/E Ratio | ★ N/A | $18.64 |
| Revenue Growth | 4.14 | ★ 9.93 |
| 52 Week Low | $95.49 | $31.90 |
| 52 Week High | $182.99 | $49.62 |
Technical Indicators
Market Signals| Indicator | JAZZ | EXEL |
|---|---|---|
| Relative Strength Index (RSI) | 58.58 | 68.79 |
| Support Level | $164.39 | $40.83 |
| Resistance Level | $172.00 | $42.09 |
| Average True Range (ATR) | 4.28 | 1.23 |
| MACD | -1.26 | 0.19 |
| Stochastic Oscillator | 78.09 | 99.02 |
Price Performance
Historical ComparisonAbout JAZZ Jazz Pharmaceuticals plc (Ireland)
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
About EXEL Exelixis Inc.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.